Cancer Cell

Papers
(The H4-Index of Cancer Cell is 107. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Accelerated approvals: Early-phase success or premature authorization?2425
Lymphoma accelerates T cell and tissue aging637
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer616
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer571
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer449
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition441
TAMing immunity through an unexpected source394
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton390
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling386
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression368
Characterization of the generic mutant p53-rescue compounds in a broad range of assays358
KIT as a therapeutic target in neuroendocrine prostate cancer324
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients314
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture305
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer298
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas297
Long-range cholinergic input promotes glioblastoma progression287
Spatial profiling technologies illuminate the tumor microenvironment281
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations263
Diet-microbiome interactions in cancer262
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target261
Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses261
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation258
B cell heterogeneity in cancer comes of age257
Bacteria in metastatic sites: Unveiling hidden players in cancer progression256
The aging lung microenvironment awakens melanoma metastases253
Cancer vaccines253
T cell dynamism and immune-related adverse events251
A holistic view of cancer249
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma247
High endothelial venules in cancer: Regulation, function, and therapeutic implication244
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer241
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer238
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma238
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses233
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer218
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors208
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer204
Challenges in neoantigen-directed therapeutics203
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity203
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer201
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin200
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments196
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron196
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics193
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer193
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts189
Immunosensitivity cuts across mismatch repair status in colorectal cancer181
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation177
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas174
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma171
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors169
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma168
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma166
A genetic portrait of metastatic seeds in lung adenocarcinoma165
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation163
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding162
Challenges and opportunities for modeling aging and cancer160
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells158
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?157
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients156
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer155
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population154
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma154
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression153
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer150
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis149
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification148
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy148
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy148
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer147
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma143
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies142
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis138
Tumor-infiltrating lymphocytes: A new hope136
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes134
Midkine as a driver of age-related changes and increase in mammary tumorigenesis132
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD131
A path to translation: How 3D patient tumor avatars enable next generation precision oncology130
Integrated proteogenomic characterization of glioblastoma evolution130
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells128
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions127
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1127
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers127
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells126
Immune determinants of the pre-metastatic niche123
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness122
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring122
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment122
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells120
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy120
A circular RNA in neuroendocrine carcinomas119
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma118
New horizons at the interface of artificial intelligence and translational cancer research117
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance117
Proteogenomic data and resources for pan-cancer analysis116
The winner takes it all: Competition drives clonal selection in gliomagenesis116
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma115
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest112
GDF15 research from bench to bedside111
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study110
Tumors on different wavelengths110
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma110
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers110
Firing up neutrophil anti-tumor immunity with cocktails109
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment108
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial107
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma107
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma107
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer107
0.28271198272705